Leguia Mariana, Vila-Sanjurjo Antón, Juarez Diana, Garcia-Glaessner Alejandra, Gil Ana I, Alvarez Mayita, Cornejo Rubelio, Cherikh Sami, Gelber Casey E, Goll Johannes B, Howard Leigh M, Jimenez-Truque Natalia, Edwards Kathryn M, Creech C Buddy, Lanata Claudio F
Genomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru.
CICA - Centro Interdisciplinar de Química e Bioloxía, Departamento de Bioloxía, Facultade de Ciencias, Universidade da Coruña, Campus de Elviña, Coruña, Spain.
NPJ Vaccines. 2025 Aug 11;10(1):188. doi: 10.1038/s41541-025-01121-0.
Given the local and systemic adverse reactions associated with whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids (DTP), acellular pertussis vaccines combined with the same toxoids (DTaP) were developed in the 1990s. In comparison to DTP, DTaP vaccines demonstrated reduced reactogenicity and equivalent or improved immunogenicity and efficacy. However, there has been a resurgence of pertussis disease, particularly in DTaP-vaccinated children, suggesting that immunity wanes more quickly with DTaP vaccination. To elucidate the differences in immune responses to DTP and DTaP vaccines, we employed a systems biology-based strategy to compare global changes in gene expression following primary vaccination with either DTP or DTaP. We used RNA-Seq and ribosome profiling (RP) to identify transcriptional and translational signatures, respectively, in peripheral blood mononuclear cells (PBMCs) collected from 50 infant recipients of DTP or DTaP at two time-points (baseline (pre-vaccination at Day 1) and either Day 2 or 8 post-vaccination). We also used standard serologic methods to assess immunogenicity, and correlated these results with transcriptional and translational signatures. Here, we provide a detailed description of the rationale, experimental design, methodology, and enrollment procedures used. Given the technical complexity of our approach, our objective is to fill knowledge gaps, describe key quality metrics, and support future publications. In brief, we recovered 4-12 million PBMCs (average 8.9 million) with 99% viability per 2.5 mL blood sample, enabling excellent nucleic acid recovery yields for the preparation of high-quality sequencing libraries. In turn, these generated RNA-Seq and RP datasets with sufficient genome coverage breadth and depth to enable differential gene expression analyses, demonstrating the validity of this approach to study pertussis vaccine immunology specifically, and its utility to characterize mechanisms of the human immune response to vaccination generally.
鉴于全细胞百日咳疫苗与白喉和破伤风类毒素联合使用(DTP)会产生局部和全身不良反应,20世纪90年代研发出了与相同类毒素联合使用的无细胞百日咳疫苗(DTaP)。与DTP相比,DTaP疫苗的反应原性降低,免疫原性和效力相当或有所提高。然而,百日咳疾病有所复发,尤其是在接种DTaP疫苗的儿童中,这表明接种DTaP疫苗后免疫力下降更快。为了阐明对DTP和DTaP疫苗免疫反应的差异,我们采用了基于系统生物学的策略,比较初次接种DTP或DTaP后基因表达的整体变化。我们使用RNA测序(RNA-Seq)和核糖体分析(RP)分别在两个时间点(基线(第1天接种前)和接种后第2天或第8天)从50名接种DTP或DTaP的婴儿受种者采集的外周血单核细胞(PBMC)中鉴定转录和翻译特征。我们还使用标准血清学方法评估免疫原性,并将这些结果与转录和翻译特征相关联。在此,我们详细描述了所使用的原理、实验设计、方法和入组程序。鉴于我们方法的技术复杂性,我们的目标是填补知识空白、描述关键质量指标并支持未来的出版物。简而言之,我们每2.5 mL血样回收了400 - 1200万个PBMC(平均890万个),活力为99%,这使得制备高质量测序文库时核酸回收率极高。相应地,这些产生了具有足够基因组覆盖广度和深度的RNA-Seq和RP数据集,能够进行差异基因表达分析,证明了这种方法专门用于研究百日咳疫苗免疫学的有效性,以及其总体上用于表征人类对疫苗接种免疫反应机制的效用。